PMC8627268_01
(A-C) Right lung lesions showed by CT scan (arrows). (A) Right upper lobe mass (arrow) measures approximately 4.0 cm shows in the first chest CT scan. (B) The lung lesions shrunk after PD-1/PD-L1 inhibitors treatment. (C) The lung lesions remained stable after discontinuation of pembrolizumab for eight month. (D-F) Liver metastatic lesions shown by CT scan. (D) Liver metastatic lesions (arrow) measures approximately 1.7 cm showsin the first abdominal CT scan. (E) Liver metastatic lesions measures approximately 1.1 cm after PD-1/PD-L1 inhibitors treatment. (F) Liver metastatic lesions disappeared after discontinuation of pembrolizumab for eight month.
OTT-14-5309-g0001.jpg
PMC8627268_01_OTT-14-5309-g0001.jpg
f0001
The patient remained in partial disease remission when undergoing CT (as shown in Figure 1). Fortunately, the lung lesions remained stable, while the liver metastatic lesions disappeared after discontinuation of pembrolizumab for eight month (as shown in Figure 1).
Electrocardiography obtained on admission for abnormal manifestations of serum myocardial enzyme spectrum. Rate of 168 beats per minute. Intervals in milliseconds: PR 70, QRS duration 68, QT 186, QTc 274. The electrocardiography indicated atrial fibrillation (fast ventricular rate type).
OTT-14-5309-g0002.jpg
PMC8627268_01_OTT-14-5309-g0002.jpg
f0002
In addition, ECG characteristics distinctly indicated atrial fibrillation (fast ventricular rate type) as shown in Figure 2.